Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David P Meeker
AddedFeb 15, 2024
UpdatedMay 31, 2026
David P Meeker

David P Meeker

CEO, Genzyme

CrunchbaseLinkedIn

David P Meeker's Career

Genzyme
Genzyme

Cambridge, MA, US

CEO· C-Suite · Management
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals

Boston, MA, US

Board Member· Board
KSQ Therapeutics
KSQ Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David P Meeker's Career

Genzyme
Genzyme
Acquired01981Cambridge, MA, US
CEO· C-Suite · Management

Leadership at Genzyme

Douglas A. BerthiaumeDouglas A. BerthiaumeBoard Member
Mark LevinMark LevinBoard Member
Dr Steven J BurakoffDr Steven J BurakoffBoard Member
Virgil D ThompsonVirgil D ThompsonBoard Member

Similar to Genzyme

BiogenBiogenCambridge, MA, USPharmaceuticals, Therapiesest. 1978BiogenCambridge, MA, US · est. 1978

Global biotech leader in neurology, oncology, and immunology therapies for various diseases.

Public · $1.5B8.7k
GenentechGenentechSouth San Francisco, CA, USBiopharmaceuticalsest. 1976GenentechSouth San Francisco, CA, US · est. 1976

Genentech, Inc.: A pioneering US biotech firm, operating as an independent subsidiary of Roche.

Public13.5k
Ultragenyx PharmaceuticalUltragenyx PharmaceuticalNovato, CA, USBiotech, Pharmaceuticalsest. 2010Ultragenyx PharmaceuticalNovato, CA, US · est. 2010

Ultragenyx, a US biopharmaceutical firm, innovates treatments for rare genetic diseases across various disease categories.

Public · $789.3M1.3k
Cogent BiosciencesCogent BiosciencesWaltham, MA, USBiotech, Therapiesest. 2014Cogent BiosciencesWaltham, MA, US · est. 2014

US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.

Public · $692.7M138
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Public$895.5M1772010Boston, MA, US
Board Member· Board

Leadership at Rhythm Pharmaceuticals

Ed MathersEd MathersBoard Member
Jennifer GoodJennifer GoodBoard Member
Christophe JeanChristophe JeanBoard Member
Bart HendersonBart HendersonCo-Founder
Elizabeth StonerElizabeth StonerCo-Founder
KSQ Therapeutics
KSQ Therapeutics
Series C$156M852015Cambridge, MA, US
Board Member· Board

Leadership at KSQ Therapeutics

Mahesh KarandeMahesh KarandeBoard Member
David M. SabatiniDavid M. SabatiniFounder
George GolumbeskiGeorge GolumbeskiBoard Member
Frank StegmeierFrank StegmeierBoard Member
Pearl HuangPearl HuangBoard Member
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member

Similar to KSQ Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Celsius TherapeuticsCelsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72

David P Meeker's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to David P Meeker

Tommy McNultyTommy McNultyCo-Founder · RhythmShawn KumarShawn KumarCEO · RhythmSciencePaul GilbertPaul GilbertCEO · HealthRhythmsDavid CollierDavid CollierCEO · X-37David R EpsteinDavid R EpsteinBoard Member · Valo HealthRonald GoldRonald GoldBoard Member · NJ Bio